利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

78 条记录 (耗时 0.053 秒)

    SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
    11.
    发明申请
    SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS 审中-公开
    作为CANNABINOID-1受体调节剂的取代的吡咯并[2,3-D]吡啶衍生物

    公开(公告)号：US20100063032A1

    公开(公告)日：2010-03-11

    申请号：US12529852

    申请日：2008-03-24

    申请人： John S. Debenham ,  Christina B. Madsen-Duggan ,  Thomas F. Walsh

    发明人： John S. Debenham ,  Christina B. Madsen-Duggan ,  Thomas F. Walsh

    IPC分类号： A61K31/519 ,  C07D471/04 ,  A61K31/551 ,  A61K31/541 ,  A61K31/5377 ,  A61P3/04 ,  A61P25/28 ,  A61P25/16 ,  A61P25/22 ,  A61P25/24 ,  A61P25/18 ,  A61P25/30

    CPC分类号： C07D471/04

    摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer s disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.

    摘要翻译： 结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，阿尔茨海默病，偏头痛，神经病，包括多发性硬化症和神经 - 巴利综合征的神经炎症性疾病以及病毒性炎症后遗症的中枢作用药物 脑炎，脑血管意外和头部创伤，焦虑障碍，压力，癫痫，帕金森病，运动障碍和精神分裂症。 这些化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻，肝硬化，非酒精性脂肪性肝病（NAFLD ），非酒精性脂肪性肝炎（NASH），以及促进觉醒。

    Substituted furo[2,3-b]pyridine derivatives
    12.
    发明授权
    Substituted furo[2,3-b]pyridine derivatives 失效
    取代的呋喃并[2,3-b]吡啶衍生物

    公开(公告)号：US07091216B2

    公开(公告)日：2006-08-15

    申请号：US10521821

    申请日：2003-08-01

    申请人： Richard B. Toupence ,  John S. Debenham ,  Mark T. Goulet ,  Christina B. Madsen-Duggan ,  Thomas F. Walsh ,  Shrenik K. Shah

    发明人： Richard B. Toupence ,  John S. Debenham ,  Mark T. Goulet ,  Christina B. Madsen-Duggan ,  Thomas F. Walsh ,  Shrenik K. Shah

    IPC分类号： A61K31/44 ,  C07D409/02

    CPC分类号： C07D491/04 ,  C07D453/06

    摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

    摘要翻译： 结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，偏头痛，神经病，包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症，脑血管 事故和头部创伤，焦虑症，压力，癫痫，帕金森病，运动障碍和精神分裂症。 这些化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻和肝硬化。

    Substituted naphthyridinone derivatives
    13.
    发明授权
    Substituted naphthyridinone derivatives 失效
    取代的萘啶酮衍生物

    公开(公告)号：US07728141B2

    公开(公告)日：2010-06-01

    申请号：US10576796

    申请日：2004-10-29

    申请人： John S. Debenham ,  George A. Doss ,  Christina B. Madsen-Duggan ,  Thomas F. Walsh

    发明人： John S. Debenham ,  George A. Doss ,  Christina B. Madsen-Duggan ,  Thomas F. Walsh

    IPC分类号： C07D471/04 ,  A61K31/4375

    CPC分类号： C07D471/04 ,  A61K31/4375 ,  C07D471/14

    摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

    摘要翻译： 结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，偏头痛，神经病，包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症，脑血管 事故和头部创伤，焦虑症，压力，癫痫，帕金森病，运动障碍和精神分裂症。 这些化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻和肝硬化。

    Substituted 2,3-diphenyl pyridines
    14.
    发明授权
    Substituted 2,3-diphenyl pyridines 失效
    取代的2,3-二苯基吡啶

    公开(公告)号：US07271266B2

    公开(公告)日：2007-09-18

    申请号：US10508043

    申请日：2003-03-24

    申请人： Paul E. Finke ,  Laura C. Meurer ,  John S. Debenham ,  Richard B. Toupence ,  Thomas F. Walsh

    发明人： Paul E. Finke ,  Laura C. Meurer ,  John S. Debenham ,  Richard B. Toupence ,  Thomas F. Walsh

    IPC分类号： C07D211/82 ,  C07D211/60

    CPC分类号： C07D213/79 ,  C04B35/632 ,  C07D213/65 ,  C07D213/80 ,  C07D213/81 ,  C07D213/82 ,  C07D213/85 ,  C07D213/86 ,  C07D213/87 ,  C07D401/12

    摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

    摘要翻译： 结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，偏头痛，神经病，包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症，脑血管 事故和头部创伤，焦虑障碍，压力，癫痫，帕金森病，运动障碍和精神分裂症。 这些化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻和肝硬化。